Ownership and insider activity for Sutro Biopharma, Inc. (STRO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation.
Price
| Price | $15.60 |
| Market Cap | $151M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-05 | Wigginton Jon Marc | A-Award | 10,000 | $261K |
| 2026-06-05 | Petree Daniel H | A-Award | 10,000 | $261K |
| 2026-06-05 | PANEK JAMES P | A-Award | 10,000 | $261K |
| 2026-06-05 | Lobacki Joseph M | A-Award | 10,000 | $261K |
| 2026-06-05 | Jagpal Sukhi | A-Award | 10,000 | $261K |
| 2026-06-05 | Hunter Heidi | A-Award | 10,000 | $261K |
| 2026-06-05 | Dybbs Michael | A-Award | 10,000 | $261K |
| 2026-06-05 | MATSUI CONNIE | A-Award | 10,000 | $261K |
| 2026-06-02 | Chow Gregory K. | M-Exempt | 2,500 | |
| 2026-06-02 | Chow Gregory K. | M-Exempt | 2,500 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.6M | $22.0M | $125.3M | $5.0M | $206.2M | $30.4M | $47.3M | $69.3M | $190.3M | $58.1M |
| Short-term Investments | $35.9M | 0 | $79.2M | $112.9M | $162.0M | $167.5M | $287.1M | $306.4M | $126.6M | $83.3M |
| Receivables | $577000 | $1.6M | $2.5M | $6.3M | $5.6M | $12.5M | $7.1M | $36.1M | $8.6M | $4.0M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $49.7M | $25.6M | $209.9M | $128.6M | $378.2M | $218.5M | $353.2M | $421.5M | $343.3M | $150.9M |
| Property, Plant & Equipment | $18.7M | $14.0M | $10.9M | $9.6M | $12.9M | $51.6M | $51.1M | $44.8M | $35.9M | $21.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $69.3M | $40.8M | $223.1M | $156.4M | $394.1M | $341.4M | $406.9M | $470.7M | $387.2M | $173.8M |
| Accounts Payable | $3.4M | $2.9M | $3.1M | $5.6M | $5.5M | $6.0M | $4.8M | $9.4M | $10.5M | $7.6M |
| Short-term Debt | 0 | $14.6M | $4.7M | $1.0M | 0 | $9.4M | $17.1M | $4.1M | 0 | 0 |
| Total Current Liabilities | $50.2M | $32.0M | $36.4M | $33.0M | $29.6M | $41.7M | $66.5M | $93.7M | $131.9M | $75.1M |
| Long-term Debt | 0 | 0 | $10.0M | $8.9M | $24.5M | $15.7M | $3.8M | 0 | 0 | 0 |
| Total Liabilities | $160.2M | $149.8M | $91.6M | $58.6M | $62.1M | $88.8M | $189.9M | $321.1M | $342.6M | $306.3M |
| Retained Earnings | -$95.3M | -$115.0M | -$150.3M | -$195.7M | -$227.9M | -$333.4M | -$452.6M | -$559.4M | -$786.9M | -$978.0M |
| Total Equity | -$90.9M | -$109.0M | $131.5M | $97.8M | $332.0M | $252.6M | $217.0M | $149.6M | $44.6M | -$132.5M |
| Total Debt | $1.2M | $14.6M | $14.7M | $9.9M | $24.5M | $57.4M | $55.0M | $33.6M | $23.2M | $15.7M |
| Net Debt | -$46.3M | -$7.4M | -$189.8M | -$108.0M | -$343.6M | -$140.6M | -$279.3M | -$342.0M | -$293.7M | -$125.8M |
| Working Capital | -$493000 | -$6.3M | $173.5M | $95.6M | $348.6M | $176.8M | $286.6M | $327.8M | $211.4M | $75.8M |
Financial Health
| Debt / Equity | -0.10 |
| Current Ratio | 3.32 |
Profitability
| Return on Equity | 185.30% |
| Return on Invested Capital | -95.49% |
| Return on Assets | -92.89% |
| Gross Margin | 97.20% |
| Operating Margin | -309.87% |
| Net Margin | -395.25% |
Related companies: ADVM · ARTV · CNTB · DTIL · GUTS · IFRX · KLRS
Explore sector: Healthcare · Biotechnology
More sections of STRO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks